Guggenheim Capital LLC Makes New $322,000 Investment in Scholar Rock Holding Co. (NASDAQ:SRRK)

Guggenheim Capital LLC purchased a new stake in Scholar Rock Holding Co. (NASDAQ:SRRK) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 7,440 shares of the company’s stock, valued at approximately $322,000.

A number of other institutional investors have also recently modified their holdings of the business. Barclays PLC raised its position in Scholar Rock by 103.4% in the third quarter. Barclays PLC now owns 165,449 shares of the company’s stock worth $1,324,000 after acquiring an additional 84,118 shares in the last quarter. Geode Capital Management LLC raised its position in Scholar Rock by 8.5% in the third quarter. Geode Capital Management LLC now owns 1,543,025 shares of the company’s stock worth $12,361,000 after acquiring an additional 120,489 shares in the last quarter. Exome Asset Management LLC purchased a new position in Scholar Rock in the third quarter worth $1,115,000. JPMorgan Chase & Co. raised its position in Scholar Rock by 1.0% in the third quarter. JPMorgan Chase & Co. now owns 38,726 shares of the company’s stock worth $310,000 after acquiring an additional 379 shares in the last quarter. Finally, GAMMA Investing LLC raised its position in Scholar Rock by 51.8% in the fourth quarter. GAMMA Investing LLC now owns 788 shares of the company’s stock worth $34,000 after acquiring an additional 269 shares in the last quarter. 91.08% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Scholar Rock

In related news, Director Katie Peng sold 1,006 shares of the company’s stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $34.42, for a total value of $34,626.52. Following the sale, the director now owns 30,319 shares of the company’s stock, valued at approximately $1,043,579.98. This represents a 3.21 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Tracey Sacco sold 6,500 shares of the stock in a transaction on Monday, March 24th. The stock was sold at an average price of $33.08, for a total value of $215,020.00. Following the transaction, the insider now directly owns 71,750 shares in the company, valued at approximately $2,373,490. This represents a 8.31 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 250,231 shares of company stock valued at $9,056,086. 13.30% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Separately, Wedbush reiterated an “outperform” rating and issued a $50.00 price objective on shares of Scholar Rock in a research report on Tuesday, March 25th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $42.67.

Scholar Rock Stock Down 4.6 %

SRRK stock opened at $32.81 on Monday. The company has a debt-to-equity ratio of 0.63, a current ratio of 3.88 and a quick ratio of 3.88. Scholar Rock Holding Co. has a 12 month low of $6.76 and a 12 month high of $46.98. The firm has a market capitalization of $3.11 billion, a PE ratio of -13.96 and a beta of 0.56. The company’s 50 day simple moving average is $32.77 and its 200-day simple moving average is $35.72.

Scholar Rock Company Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.